New pill could help people with low platelet disorder
Disease control
Ongoing
This phase 3 trial tests an oral drug called rilzabrutinib in 232 adults and adolescents with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive either rilzabrutinib or a placebo…
Phase: PHASE3 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC